Crossmark

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

Published Online: 2015-07-04

Published Print: 2015-09

Authors

Gupta, Neeraj

Huh, Yeamin

Hutmacher, Matthew M.

Ottinger, Sean

Hui, Ai-Min

Venkatakrishnan, Karthik
Funding

Funding for this research was provided by:

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
License Information

Text and Data Mining valid from 2015-07-04

Document is current